VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2015 | Results for the follow-up of the RESPONSE study

Jean-Jacques Kiladjian • 2 Jun 2015
ASCO 2015
Myeloproliferative Neoplasms Ruxolitinib

Dr Jean-Jacques Kiladjian discusses the results of the follow up to the RESPONSE study of ruxolitinib versus standard therapy for the treatment of patients with polycythemia vera.

More from Jean-Jacques Kiladjian

2:28
PROUD-PV and MPD-RC 112 trials of interferon alpha vs hydroxyurea for MPNs
Jean-Jacques Kiladjian • 1 Dec 2016
2:30
The role of red cell mass measurement in the diagnosis of polycythemia vera
Jean-Jacques Kiladjian • 16 May 2022
1:41
Updates on ropeginterferon in MPNs
Jean-Jacques Kiladjian • 22 Aug 2022
1:10
MPNs: genomic updates from ASH 2020
Jean-Jacques Kiladjian • 11 Dec 2020

Related Videos

1:06
Allo-HSCT in BCR-ABL-negative MPN pretreated with JAK inhibitors
Ivan Moiseev
6:57
Key updates in MPNs from ASH 2018
Claire Harrison
5:24
KRT‑232: first-in-class MDM2I for myelofibrosis R/R to JAK inhibitor therapy
Haifa Kathrin Al-Ali
5:25
Rapid responses with targeted agent in Phase I trial for systemic mastocytosis
Daniel DeAngelo
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals